KR101714359B1 - 발암성, 종양 진행 및 치료 효능을 평가하는 분석 시스템 - Google Patents

발암성, 종양 진행 및 치료 효능을 평가하는 분석 시스템 Download PDF

Info

Publication number
KR101714359B1
KR101714359B1 KR1020107018492A KR20107018492A KR101714359B1 KR 101714359 B1 KR101714359 B1 KR 101714359B1 KR 1020107018492 A KR1020107018492 A KR 1020107018492A KR 20107018492 A KR20107018492 A KR 20107018492A KR 101714359 B1 KR101714359 B1 KR 101714359B1
Authority
KR
South Korea
Prior art keywords
decrease
tissue sample
protein
apoptosis
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020107018492A
Other languages
English (en)
Korean (ko)
Other versions
KR20100131435A (ko
Inventor
니븐 라진 나레인
인더세카르 퍼사우드
Original Assignee
베르그 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 베르그 엘엘씨 filed Critical 베르그 엘엘씨
Publication of KR20100131435A publication Critical patent/KR20100131435A/ko
Application granted granted Critical
Publication of KR101714359B1 publication Critical patent/KR101714359B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Chemical Kinetics & Catalysis (AREA)
KR1020107018492A 2008-01-25 2009-01-26 발암성, 종양 진행 및 치료 효능을 평가하는 분석 시스템 Expired - Fee Related KR101714359B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US2357008P 2008-01-25 2008-01-25
US61/023,570 2008-01-25
PCT/US2009/031957 WO2009094619A1 (en) 2008-01-25 2009-01-26 Assay system for the assessment of oncogenicity, tumor progression, and treatment efficacy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020157030263A Division KR101711860B1 (ko) 2008-01-25 2009-01-26 발암성, 종양 진행 및 치료 효능을 평가하는 분석 시스템

Publications (2)

Publication Number Publication Date
KR20100131435A KR20100131435A (ko) 2010-12-15
KR101714359B1 true KR101714359B1 (ko) 2017-03-09

Family

ID=40901454

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020107018492A Expired - Fee Related KR101714359B1 (ko) 2008-01-25 2009-01-26 발암성, 종양 진행 및 치료 효능을 평가하는 분석 시스템
KR1020157030263A Expired - Fee Related KR101711860B1 (ko) 2008-01-25 2009-01-26 발암성, 종양 진행 및 치료 효능을 평가하는 분석 시스템

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020157030263A Expired - Fee Related KR101711860B1 (ko) 2008-01-25 2009-01-26 발암성, 종양 진행 및 치료 효능을 평가하는 분석 시스템

Country Status (7)

Country Link
US (1) US10365279B2 (cg-RX-API-DMAC10.html)
EP (2) EP2708894B1 (cg-RX-API-DMAC10.html)
JP (3) JP2011511271A (cg-RX-API-DMAC10.html)
KR (2) KR101714359B1 (cg-RX-API-DMAC10.html)
AU (1) AU2009206289A1 (cg-RX-API-DMAC10.html)
ES (2) ES2453161T3 (cg-RX-API-DMAC10.html)
WO (1) WO2009094619A1 (cg-RX-API-DMAC10.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8475739B2 (en) 2011-09-25 2013-07-02 Theranos, Inc. Systems and methods for fluid handling
US9664702B2 (en) 2011-09-25 2017-05-30 Theranos, Inc. Fluid handling apparatus and configurations
US20140170735A1 (en) 2011-09-25 2014-06-19 Elizabeth A. Holmes Systems and methods for multi-analysis
US9632102B2 (en) 2011-09-25 2017-04-25 Theranos, Inc. Systems and methods for multi-purpose analysis
US9810704B2 (en) 2013-02-18 2017-11-07 Theranos, Inc. Systems and methods for multi-analysis
US10012664B2 (en) 2011-09-25 2018-07-03 Theranos Ip Company, Llc Systems and methods for fluid and component handling
KR101765999B1 (ko) 2015-01-21 2017-08-08 서울대학교산학협력단 암 바이오마커의 성능 평가 장치 및 방법
US20220088031A1 (en) * 2019-02-01 2022-03-24 Health Research, Inc. Methods and compositions for treating resistant and recurrent forms of cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040133352A1 (en) * 1999-06-28 2004-07-08 Michael Bevilacqua Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19736691A1 (de) 1997-08-22 1999-02-25 Michael Prof Dr Med Giesing Verfahren zur Charakterisierung und Identifizierung disseminierter und metastasierter Krebszellen
AU2002216009A1 (en) 2000-11-03 2002-05-15 Michael Giesing Clinical and functional validation of targets from disseminated cancer cells
US20030138792A1 (en) 2001-05-31 2003-07-24 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention and therapy of cervical cancer
CN1612936A (zh) 2001-11-09 2005-05-04 苏尔斯精细医药公司 利用基因表达分布图识别、监控和治疗疾病以及鉴定生物学状态
US20030235816A1 (en) 2002-03-14 2003-12-25 Baylor College Of Medicine (By Slawin And Shariat) Method to determine outcome for patients with prostatic disease
FR2840923B1 (fr) 2002-06-17 2007-07-06 Centre Nat Rech Scient Agent anti-resistance a l'oxaliplatine
US20040101915A1 (en) * 2002-06-18 2004-05-27 Irm Llc, A Delaware Limited Liability Company Diagnosis and treatment of chemoresistant tumors
EP1507148B1 (en) 2003-08-25 2005-02-23 MTM Laboratories AG Method for detecting carcinomas in a solubilized cervical body sample
CN1984663A (zh) 2004-03-29 2007-06-20 南佛罗里达大学 用曲西瑞宾和相关化合物有效治疗肿瘤和癌症
US20060204951A1 (en) * 2004-04-26 2006-09-14 Judah Folkman Platelet biomarkers for the detection of disease
EP1778856A4 (en) 2004-08-02 2008-05-28 Childrens Medical Center BLOOD BIOMARKER FOR CANCER
JP4678882B2 (ja) 2004-10-14 2011-04-27 ジェネンテック， インコーポレイテッド Ｃｏｐ１分子およびその使用
US8700335B2 (en) * 2006-05-18 2014-04-15 Caris Mpi, Inc. System and method for determining individualized medical intervention for a disease state

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040133352A1 (en) * 1999-06-28 2004-07-08 Michael Bevilacqua Identification, monitoring and treatment of disease and characterization of biological condition using gene expression profiles

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
European J. Cancer,제41권,2213-36면(2005)*
The Oncologist,제9권,226-227면(2004)*

Also Published As

Publication number Publication date
EP2708894A2 (en) 2014-03-19
JP2015052605A (ja) 2015-03-19
KR101711860B1 (ko) 2017-03-03
JP6087888B2 (ja) 2017-03-01
ES2589506T3 (es) 2016-11-14
US20110027811A1 (en) 2011-02-03
KR20100131435A (ko) 2010-12-15
KR20150123344A (ko) 2015-11-03
ES2453161T3 (es) 2014-04-04
AU2009206289A1 (en) 2009-07-30
US10365279B2 (en) 2019-07-30
EP2245460A1 (en) 2010-11-03
JP2017102125A (ja) 2017-06-08
JP2011511271A (ja) 2011-04-07
EP2245460B1 (en) 2013-12-25
WO2009094619A1 (en) 2009-07-30
EP2708894B1 (en) 2016-07-06
HK1150401A1 (en) 2011-12-23
EP2245460A4 (en) 2011-05-25
EP2708894A3 (en) 2014-04-02

Similar Documents

Publication Publication Date Title
Williams et al. Prognostic significance and predictors of the neutrophil-to-lymphocyte ratio in ovarian cancer
KR101711860B1 (ko) 발암성, 종양 진행 및 치료 효능을 평가하는 분석 시스템
Witkowski et al. The influence of clinical and genetic factors on patient outcome in small cell carcinoma of the ovary, hypercalcemic type
Boegemann et al. The percentage of prostate‐specific antigen (PSA) isoform [–2] pro PSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged≤ 65 years
Yang et al. Prognostic value of Ki-67 in solid pseudopapillary tumor of the pancreas: Huashan experience and systematic review of the literature
Brück et al. Spatial immunoprofiling of the intratumoral and peritumoral tissue of renal cell carcinoma patients
Saab et al. Utility of genomic analysis in differentiating synchronous and metachronous lung adenocarcinomas from primary adenocarcinomas with intrapulmonary metastasis
Jaafari-Ashkavandi et al. MCM3 and Ki67 proliferation markers in odontogenic cysts and ameloblastoma
Porter et al. Novel biomarkers for risk stratification of Barrett’s oesophagus associated neoplastic progression–epithelial HMGB1 expression and stromal lymphocytic phenotype: Molecular Diagnostics
Naik Role of biomarkers in the integrated management of melanoma
Wang et al. Value of CXCL8–CXCR1/2 axis in neoadjuvant chemotherapy for triple-negative breast cancer patients: a retrospective pilot study
Wang et al. The significance of preoperative neutrophil-to-lymphocyte ratio in predicting short-term complications and survival benefits of pancreaticoduodenectomy: A systematic review and meta-analysis
Liu et al. Immune and inflammation: related factor alterations as biomarkers for predicting prognosis and responsiveness to PD-1 monoclonal antibodies in cervical cancer
Yu et al. Lichen planopilaris and pseudopelade of Brocq involve distinct disease associated gene expression patterns by microarray
Karaburun et al. Investigation of atypical cell parameter in the surveillance of patients with NMIBC; initial outcomes of a single center prospective study
Serra et al. Cyclooxygenase-2 (COX2) and p53 protein expression are interdependent in breast cancer but not associated with clinico-pathological surrogate subtypes, tumor aggressiveness and patient survival.
Nassir et al. HE4 tissue expression in borderline ovarian tumors: a pilot study by the tumorbank ovarian cancer network
AU2015203304B2 (en) Assay system for the assessment of oncogenicity, tumor progression, and treatment efficacy
Yang et al. Prognostic value of lymphocyte-to-monocyte ratio in patients with small cell lung cancer: a meta-analysis
Tirić et al. Immunohistochemical expression and predictive value of PAX3 and FOXO1 proteins in high-grade serous ovarian carcinoma.
HK1195623A (en) Assay system for the assessment of oncogenicity, tumor progression, and treatment efficacy
HK1195623B (en) Assay system for the assessment of oncogenicity, tumor progression, and treatment efficacy
HK1150401B (en) Assay system for the assessment of oncogenicity, tumor progression, and treatment efficacy
Dai et al. Matrix metalloproteinase 9 for evaluating invasiveness and recurrence in pituitary adenoma patients: A Meta-analysis
Rombach et al. Impact of preoperative clinical patient parameters on surgically obtained brain metastasis samples for translational research

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

A201 Request for examination
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

N231 Notification of change of applicant
PN2301 Change of applicant

St.27 status event code: A-3-3-R10-R13-asn-PN2301

St.27 status event code: A-3-3-R10-R11-asn-PN2301

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

A107 Divisional application of patent
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20200304

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20200304

P22-X000 Classification modified

St.27 status event code: A-4-4-P10-P22-nap-X000